Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

NCT ID: NCT04047862

Last Updated: 2025-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 446 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-08-15
• Study Completion Date: 2024-08-07

Brief Summary

The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1.

Primary objective of Phase 1b was to assess overall response rate (ORR) determined by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 for patients in each dose-expansion cohort.

Conditions

Locally Advanced and Metastatic Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1: Dose Escalation: Ociperlimab 50 mg + Tislelizumab 200 mg

Participants received ociperlimab 50 milligrams (mg) intravenous (IV) infusion on Day 1 of each cycle (cycle 1= 28 days) and tislelizumab 200 mg IV infusion on Day 8 of Cycle 1. If tolerated, participants received ociperlimab and tislelizumab doses IV on Cycle 2 Day 1 (cycle 2 onwards = 21 days) and thereafter every 21 days (that is, \[i.e.\], every 3 weeks \[Q3W\]) until disease progression, adverse events (AEs), participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1: Dose Escalation: Ociperlimab 150 mg + Tislelizumab 200 mg

Participants received ociperlimab 150 mg IV infusion on Day 1 of each cycle (cycle 1= 28 days) and tislelizumab 200 mg IV infusion on Day 8 of Cycle 1. If tolerated, participants received ociperlimab and tislelizumab doses IV on Cycle 2 Day 1 (cycle 2 onwards = 21 days) and thereafter every 21 days (i.e. Q3W) until disease progression, intolerable toxicity, or withdrawal of consent.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1: Dose Escalation: Ociperlimab 450 mg + Tislelizumab 200 mg

Participants received ociperlimab 450 mg IV infusion on Day 1 of each cycle (cycle 1= 28 days) and tislelizumab 200 mg IV infusion on Day 8 of Cycle 1. If tolerated, participants received ociperlimab and tislelizumab doses IV on Cycle 2 Day 1 (cycle 2 onwards = 21 days) and thereafter every 21 days (i.e. Q3W) until disease progression, intolerable toxicity, or withdrawal of consent.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1: Dose Escalation: Ociperlimab 900 mg + Tislelizumab 200 mg

Participants received ociperlimab 900 mg IV infusion on Day 1 of each cycle (cycle 1= 28 days) and tislelizumab 200 mg IV infusion on Day 8 of Cycle 1. If tolerated, participants received ociperlimab and tislelizumab doses IV on Cycle 2 Day 1 (cycle 2 onwards = 21 days) and thereafter every 21 days (i.e. Q3W) until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1: Dose Escalation: Ociperlimab 1800 mg + Tislelizumab 200 mg

Participants received ociperlimab 1800 mg IV infusion on Day 1 of each cycle (cycle 1= 28 days) and tislelizumab 200 mg IV infusion on Day 8 of Cycle 1. If tolerated, participants received ociperlimab and tislelizumab doses IV on Cycle 2 Day 1 (cycle 2 onwards = 21 days) and thereafter every 21 days (i.e. Q3W) until disease progression, intolerable toxicity, or withdrawal of consent.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1: Dose Verification: Cohort 1A (Ociperlimab 900 mg)

Participants received ociperlimab 900 mg as monotherapy IV infusion on Day 1 of each 21-day treatment cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Phase 1: Dose Verification: Cohort 1B (Ociperlimab 900 mg + Tislelizumab 200 mg)

Participants received ociperlimab 900 mg as IV infusion on Day 1 of each 21-day treatment cycle and tislelizumab 200 mg IV infusion once every 21 days (i.e. Q3W) until disease progression, intolerable toxicity, or withdrawal of consent.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1b: Dose Expansion: Cohort 1

Participants with metastatic squamous non-small cell lung cancer (NSCLC) received treatment with ociperlimab 900 mg IV infusion along with tislelizumab 200 mg IV infusion on Day 1 of each 21-day cycle. Participants also received 4 to 6 cycles of chemotherapy with carboplatin at an area under the curve (AUC) 5 or 6 (Day 1) + paclitaxel 200 or 175 mg/m\^2 (Day 1) or nab paclitaxel 100 mg/m\^2 (Days 1, 8 and 15) Q3W p until disease progression, intolerable toxicity, or withdrawal of consent.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Paclitaxel

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Nab paclitaxel

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Carboplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Phase 1b: Dose Expansion: Cohort 2

Participants with metastatic non-squamous NSCLC received treatment with ociperlimab 900 mg IV infusion and tislelizumab 200 mg IV infusion on Day 1 of each 21-day cycle. Participants also received cisplatin 75 mg/m\^2 or carboplatin (AUC 5) and pemetrexed 500 mg/m\^2 (on Day 1) Q3W for 4-6 cycles followed by ociperlimab 900 mg + tislelizumab 200 mg + pemetrexed 500 mg/m\^2 on Day 1 Q3W until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Pemetrexed

Intervention Type: DRUG

Administered in accordance with local guidelines, prescribing information/summary of product

Carboplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Cisplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Phase 1b: Dose Expansion: Cohort 3

Participants with metastatic NSCLC (programmed cell death protein-ligand 1 \[PD-L1\] positive, tumor cell \[TC\] \>=1%) were treated with ociperlimab 900 mg IV infusion and tislelizumab 200 mg IV infusion on Day 1 of each 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1b: Dose Expansion: Cohort 4

Participants with extensive-stage small-cell lung cancer (SCLC) received treatment with ociperlimab 900 mg IV infusion, tislelizumab 200 mg IV infusion. Participants also received 4 cycles of etoposide 100 mg/m\^2 (on Days 1, 2, 3), and cisplatin 75 mg/m\^2 or carboplatin AUC 5 (Day 1) Q3W, followed by ociperlimab 900 mg (Day 1) + tislelizumab 200 mg (Day 1) Q3W until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Carboplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Cisplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Etoposide

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Phase 1b: Dose Expansion: Cohort 5

Checkpoint inhibitor (CPI)-experienced NSCLC participants received treatment with ociperlimab 900 mg IV infusion and tislelizumab 200 mg IV infusions on Day 1 of each 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1b: Dose Expansion: Cohort 6

Participants with metastatic esophageal squamous cell carcinoma (ESCC) received treatment with 6 cycles of ociperlimab 900 mg (Day 1) IV infusion, tislelizumab 200 mg (Day 1) IV infusion, cisplatin 75 mg/m\^2 (Day 1), and 5-fluorouracil 750-800 mg/m\^2 (5-FU; Day 1 to Day 5) or paclitaxel 200 or 175 mg/m\^2 (Day 1) Q3W followed by ociperlimab 900 mg and tislelizumab 200 mg on Day 1 of every 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Paclitaxel

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Cisplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

5fluorouracil

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Phase 1b: Dose Expansion: Cohort 7

Participants with metastatic esophageal adenocarcinoma (EAC) received treatment with 6 cycles of ociperlimab 900 mg (Day 1) IV infusion, tislelizumab 200 mg (Day 1) IV infusion, cisplatin 75 mg/m\^2 (Day 1), and 5-Fluorouracil 750-800 mg/m\^2 (5-FU; Day 1 to Day 5) or paclitaxel 200 or 175 mg/m\^2 (Day 1) Q3W followed by ociperlimab 900 mg and tislelizumab 200 mg on Day 1 of every 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Paclitaxel

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Cisplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

5fluorouracil

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Phase 1b: Dose Expansion: Cohort 8

Participants with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC; PD-L1 positive, visually estimated Combined Positive Score \[vCPS\] \>= 1%) received treatment with ociperlimab 900 mg IV infusion and tislelizumab 200 mg IV infusions on Day 1 of every 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1b: Dose Expansion: Cohort 9

Participants with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma received treatment with 6 cycles of ociperlimab 900 mg (Day 1) IV infusion, tislelizumab 200 mg (Day 1) IV infusion, (oxaliplatin 1300 mg/m\^2 \[Day 1\] and capecitabine 1000 mg/m\^2 \[Day 1-14 twice daily\]), or (cisplatin 75 mg/m\^2 \[Day\], and 5-FU 750-800 mg/m\^2 \[Day 1-5\]) Q3W followed by ociperlimab 900 mg (Day 1), tislelizumab 200 mg (Day 1) + capecitabine 1000 mg/m\^2 twice daily (Day 1-14) Q3W until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Cisplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

5fluorouracil

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Oxaliplatin

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Capecitabine

Intervention Type: DRUG

Administered in accordance with local guidelines , prescribing information/summary of product

Phase 1b: Dose Optimization: Cohort 10: (Ociperlimab 450 mg + Tislelizumab 200 mg)

articipants with metastatic NSCLC (PD-L1 positive, TC \>= 1%) received treatment with ociperlimab 450 mg IV infusion and tislelizumab 200 mg IV infusion on Day 1 of every 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1b: Dose Optimization: Cohort 10: (Ociperlimab 900 mg + Tislelizumab 200 mg)

Participants with metastatic NSCLC (PD-L1 positive, TC \>= 1%) received treatment with ociperlimab 900 mg IV infusion and tislelizumab 200 mg IV infusion on Day 1 of every 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Phase 1b: Dose Optimization: Cohort 10: (Ociperlimab 1800 mg + Tislelizumab 200 mg)

Participants with metastatic NSCLC (PD-L1 positive, TC \>= 1%) received treatment with ociperlimab 1800 mg IV infusion and tislelizumab 200 mg IV infusion on Day 1 of every 21-day cycle until disease progression, AEs, participant withdrew consent, lost to follow-up or death, whichever came first.

Group Type: EXPERIMENTAL

Ociperlimab

Intervention Type: DRUG

Administered as an intravenous (IV) injection

Tislelizumab

Intervention Type: DRUG

Administered as an IV injection

Interventions

Ociperlimab

Administered as an intravenous (IV) injection

Intervention Type: DRUG

Tislelizumab

Administered as an IV injection

Intervention Type: DRUG

Pemetrexed

Administered in accordance with local guidelines, prescribing information/summary of product

Intervention Type: DRUG

Paclitaxel

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

Nab paclitaxel

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

Carboplatin

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

Cisplatin

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

Etoposide

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

5fluorouracil

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

Oxaliplatin

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

Capecitabine

Administered in accordance with local guidelines , prescribing information/summary of product

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Had Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to (<=) 1.

2. Greater than or equal to (>=) measurable lesion per RECIST v1.1.

3. Had adequate organ function.

4. Phase 1- Participants with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors who had previously received standard systemic therapy or for which treatment is not available, not tolerated or refused.

1. Signed informed consent form (ICF) and able to comply with study requirements.

2. Age >= 18 years (or the legal age of consent) at the time the ICF was signed.

3. Histologically or cytologically confirmed tumor types in the following disease cohorts:

Cohort 1: stage IV squamous NSCLC Cohort 2: stage IV non-squamous NSCLC Cohort 3: stage IV squamous or non-squamous NSCLC with PD-L1 positive. Cohort 4: extensive-stage SCLC Cohort 5: stage IIIB, IIIC or IV NSCLC Cohort 6: stage IV ESCC Cohort 7: stage IV EAC Cohort 8: recurrent or metastatic HNSCC incurable by local therapies Cohort 9: stage IV G/GEJ adenocarcinoma. Cohort 10: stage IV squamous or non-squamous NSCLC with PD-L1 positive.

4. ECOG Performance Status <= 1

5. Adequate organ function

6. Were willing to use highly effective method of birth control

Exclusion Criteria

1. Active brain or leptomeningeal metastasis.

2. Active autoimmune diseases or history of autoimmune diseases that could have relapsed.

3. Had severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc. (antiviral therapy is permitted for patients with hepatocellular carcinoma).

4. Concurrent participation in another therapeutic clinical trial.

5. Received prior therapies targeting TIGIT.

1. Participants with any prior therapy for recurrent/metastatic disease.

2. Non-squamous NSCLC patients with sensitizing epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion, and c-ros oncogene 1 (ROS1) fusion.

3. Gastric cancer participants with squamous or with positive HER2 expression.

4. Prior therapy with any drug specifically targeting T-cell co-stimulation or checkpoint pathways. (anti-PD(L)1 exception for Cohort 5).

5. Active leptomeningeal disease or uncontrolled brain metastasis.

6. Active autoimmune diseases or history of autoimmune diseases that may relapse.

7. With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc. (antiviral therapy is permitted for participants with hepatocellular carcinoma).

8. Concurrent participation in another therapeutic clinical study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BeiGene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

BeiGene

Locations

Mayo Clinic Phoenix

Phoenix, Arizona, United States

Scri Florida Cancer Specialists South

Fort Myers, Florida, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Scri Florida Cancer Specialists North

St. Petersburg, Florida, United States

University of Kansas Medical Center Research Institute

Kansas City, Kansas, United States

University of Minnesota

Minneapolis, Minnesota, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Providence Portland Medical Center

Portland, Oregon, United States

Tennessee Oncology, Pllc Nashville

Nashville, Tennessee, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Chris Obrien Lifehouse

Camperdown, New South Wales, Australia

Pindara Private Hospital

Benowa, Queensland, Australia

Icon Cancer Foundation

South Brisbane, Queensland, Australia

Metro South Health, Cancer Trials Unit Division of Cancer Services Pah

Woolloongabba, Queensland, Australia

Ashford Cancer Centre Research Northeast

Windsor Gardens, South Australia, Australia

Royal Hobart Hospital

Hobart, Tasmania, Australia

Bendigo Health

Bendigo, Victoria, Australia

Monash Health

Clayton, Victoria, Australia

St Vincents Hospital

Fitzroy, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

St John of God Health Care

Subiaco, Western Australia, Australia

The Second Hospital of Anhui Medical University

Hefei, Anhui, China

Beijing Tongren Hospital, Cmu

Beijing, Beijing Municipality, China

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Beijing Luhe Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Chongqing Cancer Hospital

Chongqing, Chongqing Municipality, China

Fujian Cancer Hospital

Fuzhou, Fujian, China

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Hubei Cancer Hospital

Wuhan, Hubei, China

Hunan Cancer Hospital

Changsha, Hunan, China

Jilin Cancer Hospital

Changchun, Jilin, China

The First Affiliated Hospital of Xian Jiaotong University

Xi'an, Shaanxi, China

Jinan Central Hospital

Jinan, Shandong, China

Weifang Peoples Hospital

Weifang, Shandong, China

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

Sichuan Cancer Hospital and Institute

Chengdu, Sichuan, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Auckland City Hospital

Auckland, , New Zealand

Nzcr Christchurch

Christchurch, , New Zealand

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

The Catholic University of Korea, St Vincents Hospital

Suwon, Gyeonggi-do, South Korea

Gyeongsang National University Hospital

Jinju, Gyeongsangnam-do, South Korea

Gachon University Gil Medical Center

Incheon, Incheon Gwang'yeogsi, South Korea

Severance Hospital Yonsei University Health System

Seoul, Seoul Teugbyeolsi, South Korea

The Catholic University of Korea, Seoul St Marys Hospital

Seoul, Seoul Teugbyeolsi, South Korea

Smg Snu Boramae Medical Center

Seoul, Seoul Teugbyeolsi, South Korea

Hualien Tzu Chi Hospital

Hualien City, , Taiwan

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Chung Shan Medical University Hospital

Taichung, , Taiwan

China Medical University Hospital

Taichung, , Taiwan

Veterans General Hospital Taichung

Taichung, , Taiwan

National Taiwan University Hospital

Taipei, , Taiwan

Taipei Veterans General Hospital

Taipei, , Taiwan

Taipei Tzu Chi Hospital

Taipei, , Taiwan

Linkou Chang Gung Memorial Hospital

Taoyuan District, , Taiwan

Countries

United States; Australia; China; New Zealand; South Korea; Taiwan

References

Frentzas S, Kao S, Gao R, Zheng H, Rizwan A, Budha N, de la Hoz Pedroza L, Tan W, Meniawy T. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors. J Immunother Cancer. 2023 Oct;11(10):e005829. doi: 10.1136/jitc-2022-005829.

Reference Type: RESULT

PMID: 37857528 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

AdvanTIG-105

Identifier Type: OTHER

Identifier Source: secondary_id

CTR20202608

Identifier Type: OTHER

Identifier Source: secondary_id

BGB-900-105

Identifier Type: -

Identifier Source: org_study_id